ArticleOncoimmunology
S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Selective elimination of circulating effector CD8 T cells via LTβR blockade separates anti-CD137 efficacy from toxicity.Science advances · 2026Article
- CD137L promotes immune surveillance in melanoma via HLTF regulation.Nature communications · 2025Article
- The multi-faceted immune modulatory role of S100A4 in cancer and chronic inflammatory disease.Frontiers in immunology · 2025Review
- Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives.Frontiers in immunology · 2023Review
- Hepatocyte-Specific Smad4 Deficiency Alleviates Liver Fibrosis via the p38/p65 Pathway.International journal of molecular sciences · 2022Article
- MyD88 in hepatic stellate cells enhances liver fibrosis via promoting macrophage M1 polarization.Cell death & disease · 2022Article
- Exosomes as Crucial Players in Pathogenesis of Systemic Lupus Erythematosus.Journal of immunology research · 2022Review
- Nanomaterials for Protein Delivery in Anticancer Applications.Pharmaceutics · 2021Review
- Update of early phase clinical trials in cancer immunotherapy.BMB reports · 2021Review
- Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.American journal of hematology · 2020Article
- S100A4 promotes hepatocellular carcinogenesis by intensifying fibrosis-associated cancer cell stemness.Oncoimmunology · 2020Article
- S100A4 promotes inflammation but suppresses lipid accumulation via the STAT3 pathway in chronic ethanol-induced fatty liver.Journal of molecular medicine (Berlin, Germany) · 2019Article
- Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity.Nature communications · 2019Article
- An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer.International journal of molecular sciences · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 3 countries.
Funding
Abstract
Liver-related autoimmune toxicities triggered by agonistic anti-CD137 antibodies have greatly limited their use in clinical applications. Here, we found that anti-CD137 monoclonal antibody (mAb) treatment in mice induced the infiltration of a large number of S100A4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.